242 related articles for article (PubMed ID: 30113697)
21. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
23. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
25. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
Roumie CL; Greevy RA; Grijalva CG; Hung AM; Liu X; Murff HJ; Elasy TA; Griffin MR
JAMA; 2014 Jun; 311(22):2288-96. PubMed ID: 24915260
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes.
Xie Y; Bowe B; Gibson AK; McGill JB; Maddukuri G; Al-Aly Z
JAMA Intern Med; 2021 Aug; 181(8):1043-1053. PubMed ID: 34180939
[TBL] [Abstract][Full Text] [Related]
27. Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
Ou HT; Chen YT; Liu YM; Wu JS
Diabetes Res Clin Pract; 2016 Jun; 116():14-25. PubMed ID: 27321311
[TBL] [Abstract][Full Text] [Related]
28. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
[TBL] [Abstract][Full Text] [Related]
29. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
30. Renal Outcomes of Pioglitazone Compared with Acarbose in Diabetic Patients: A Randomized Controlled Study.
Chen YH; Tarng DC; Chen HS
PLoS One; 2016; 11(11):e0165750. PubMed ID: 27812149
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
32. Use of an α-Glucosidase Inhibitor and the Risk of Colorectal Cancer in Patients With Diabetes: A Nationwide, Population-Based Cohort Study.
Tseng YH; Tsan YT; Chan WC; Sheu WH; Chen PC
Diabetes Care; 2015 Nov; 38(11):2068-74. PubMed ID: 26307605
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
34. Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemia.
Nyström T; Bodegard J; Nathanson D; Thuresson M; Norhammar A; Eriksson JW
Diabetes Res Clin Pract; 2017 Jan; 123():199-208. PubMed ID: 28056431
[TBL] [Abstract][Full Text] [Related]
35. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
36. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
[TBL] [Abstract][Full Text] [Related]
37. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
[No Abstract] [Full Text] [Related]
38. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
Evans JM; Ogston SA; Emslie-Smith A; Morris AD
Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
[TBL] [Abstract][Full Text] [Related]
39. Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program.
Jeon JY; Lee SJ; Lee S; Kim SJ; Han SJ; Kim HJ; Kim DJ; Kim YS; Woo JT; Ahn KJ; Nam M; Baik SH; Park Y; Lee KW
J Diabetes Investig; 2018 Sep; 9(5):1144-1152. PubMed ID: 29328551
[TBL] [Abstract][Full Text] [Related]
40. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]